Abstract:Abstract Diabetic nephropathy (DN) is the main cause of chronic kidney disease (CKD) and is characterized by elevated urinary albumin to creatinine ratio (UACR) and serum creatinine, and decreased glomerular filtration rate. Anti hypertensive agents are used for DN treatment, however, the effects of these drugs are insufficient, and the establishment of more effective treatment methods is desired. Carbohydrate responsive element binding protein (ChREBP) is one of the factors reported to be involved in the onset and progression of DN (1). Furthermore, whole body ablation of ChREBP suggested that the progression of DN was suppressed in the rodent model (2). On the other hand, the effectiveness of pharmaceutical ChREBP suppression is unclear, thus, we performed administration experiment to DN model mice using ChREBP activity inhibitor and examined the effects of pharmaceutical ChREBP activity suppression on renal function of diabetic mice. First, we established high-throughput screening system capable of detecting ChREBP activity and performed screening of Tohoku university compound library. The result compound, D-532, was ChREBP activity specific inhibitor without cell toxicity. D-532 directly binds to DNA-binding domain of ChREBP, and inhibits the transcriptional activity. We next performed administration experiment using type I DN model mice. D-532 treatment group showed an improvement tendency of the low body weight compared with that of vehicle treatment group, while it had no effect on blood glucose level. About renal functions, both of UACR and serum creatinine were significantly lower in D-532 treatment group. Importantly, renal tissues such as glomeruli and renal tubules were preserved in D-532 treatment group compared with in vehicle treatment group. In vivo as well, D-532 suppressed ChREBP target genes mRNA expression, and RNA-seq analysis with mice renal cortex RNA at the end of D-532 administration experiment indicated that D-532 suppressed excessive oxidative stress through the ChREBP activation under diabetes. These results indicate that ChREBP suppression is effective on DN rodent model, and ChREBP activity inhibitor D-532 may have potential as a new treatment for DN in the future. Reference: (1) Suzuki et al., Endocr J. 2019 Mar 28;67(3): 335-345. (2) Zhang et al., Eur Rev Med Pharmacol Sci. 2017 Jan;21(1): 42-47. Presentation: No date and time listed

Carbohydrate response element binding protein (ChREBP) modulates the inflammatory response of mesangial cells in response to glucose.

ChREBP Deficiency Suppresses Renal Inflammation and Fibrosis Via Inhibiting NLRP3 Inflammasome Activation in Diabetic Kidney Disease

C/EBP Homologous Protein Induces Mesangial Cell Apoptosis under Hyperglycemia

Carbohydrate response element-binding protein regulates lipid metabolism via mTOR complex1 in diabetic nephropathy.

ChREBP deficiency alleviates apoptosis by inhibiting TXNIP/oxidative stress in diabetic nephropathy.

ChREBP deficiency alleviates apoptosis by inhibiting TXNIP/oxidative stress in diabetic nephropathy

Knockdown of ChREBP Ameliorates Retinal Microvascular Endothelial Cell Injury and Angiogenic Responses in Diabetic Retinopathy

Glucose-Sensing ChREBP Protein in the Pathogenesis of Diabetic Retinopathy

HMGB1 is activated in type 2 diabetes mellitus patients and in mesangial cells in response to high glucose

The CREB/KMT5A complex regulates PTP1B to modulate high glucose-induced endothelial inflammatory factor levels in diabetic nephropathy

C-reactive Protein Promotes Diabetic Kidney Disease Via Smad3 Mediated NLRP3 Inflammasome Activation

PS-BPB06-3: EXAMINATION OF THE EFFECTIVENESS OF DIABETIC NEPHROPATHY TREATMENT TARGETING CHREBP ACTIVITY

Role of Increased Activity of Carbohydrate Response Element Binding Protein in Exces Sivelipid Accumulation in the Liver of Type 2 Diabetic Db/db Mouse

LBODP050 Examination Of The Effectiveness Of Diabetic Nephropathy Treatment Targeting Chrebp Activity

Carbohydrate response element‐binding protein (ChREBP) mediates decreased SNAP25 expression in islets from diabetic Goto‐Kakizaki (GK) rats

Resveratrol protects mesangial cells under high glucose by regulating the miR-1231/IGF1/ERK pathway

The Roles of Carbohydrate Response Element Binding Protein in the Relationship between Carbohydrate Intake and Diseases

Relationship Between Carbohydrate Response Element Binding Protein and Proliferation, Differentiation of Islet Β Cell

C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes

ChREBP-Mediated Regulation of Lipid Metabolism: Involvement of the Gut Microbiota, Liver, and Adipose Tissue

Down-Regulation Assession of Methyl CpG Binding Protein 2 in Diabetic Nephropathy